Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

218,521-218,550 of 319,975

filter-aware
21
Clinical trial data visualization (waterfall plot) with patient-level characteristics table below.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
22
Swimmer plot showing patient-level treatment duration, response status, and ongoing treatment status.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
23
Includes a spider plot (target lesion change) and a bar chart (allele clearance).Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
24
Includes patient case study with longitudinal MRI scans.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
25
The slide uses a timeline-style list on the left to show treatment history and a visual 'before-and-after' comparison of medical imaging on the right.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
26
Slide 26 of a pitch deck.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
27
Includes clinical trial data cut-offs and patient enrollment numbers.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
28
The slide details specific patient cohorts (2a-2e) with varying treatment histories and trial objectives.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
29
The slide uses a list of icons to define the TPP.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
30
The table highlights the clinical challenge of resistance mutations and CNS involvement across different treatment lines.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
31
The table uses a green/white color coding to indicate positive vs negative results for specific ALK-related activities.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
32
The slide uses a split-panel layout to contrast in vitro IC50 data with in vivo tumor regression data.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
33
The slide uses a bar chart for brain penetrance and a scatter plot for selectivity index to demonstrate the drug's therapeutic profile.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
34
The slide outlines the study design for NVL-655, detailing patient population, objectives, and cohort stratification.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
35
The slide uses a process flow diagram to illustrate patient enrollment and expansion cohorts.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
36
Clinical trial baseline characteristics table.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
37
Data cut-off: 8 Aug 2023. Includes specific footnotes regarding dose modifications and discontinuations.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
38
The chart demonstrates dose-proportional exposure and confirms that doses >= 50 mg QD exceed efficacy thresholds for various ALK mutations in the CNS.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
39
The chart displays patient-level data categorized by dose (15mg to 200mg) and mutation type, highlighting the efficacy of the drug in clearing specific ALK mutations.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
40
The slide presents clinical trial data for NVL-655, showing efficacy across different resistance mutation profiles and prior treatment histories.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
41
Clinical trial data visualization showing ORR and best percentage change in target lesions.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
42
The chart is a swimmer plot, a standard visualization in oncology clinical trials to show time-to-event data for individual patients.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
43
Includes two patient case studies with MRI scans showing tumor reduction.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
44
Includes clinical data points for EML4-ALK v3, G1202R, G1269A, and I1322M.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
45
The slide uses a hierarchical bulleted list to summarize clinical trial conclusions.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
46
The slide uses a clear, icon-based list to define the therapeutic profile.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
47
The slide uses three distinct chart types to demonstrate the drug's competitive advantage in a preclinical setting.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
48
Nuvalent | Investor Presentation Deck | 52 slidesNuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
49
The slide uses a hexagonal process flow to illustrate the company's strategic methodology.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
50
The slide uses a Gantt-style visualization to represent clinical trial progress.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit